T. Szpila

First‐line R‐CVP versus R‐CHOP induction immunochemotherapy for indolent lymphoma with rituximab maintenance. A multicentre, phase III randomized study by the Polish Lymphoma Research Group PLRG4

J. Zaucha, W. Knopińska-Posłuszny, J. Walewski, 2019, British journal of haematology.

Tracking Clonal Evolution of Multiple Myeloma Using Targeted Next-Generation DNA Sequencing

R. Płoski, M. Rydzanicz, J. Jakubikova, 2022, Biomedicines.

Three remissions after bortezomib therapy in a multiple myeloma patient with a ten year survival

K. Warzocha, M. Kraj, T. Szpila, 2009 .

Infectious complications in patients with acute myeloid leukemia treated according to the protocol with daunorubicin and cytarabine with or without addition of cladribine. A multicenter study by the Polish Adult Leukemia Group (PALG).

W. Jędrzejczak, K. Sułek, T. Robak, 2010, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

Ofatumumab with iphosphamide, etoposide and cytarabine for patients with transplantation‐ineligible relapsed and refractory diffuse large B‐cell lymphoma

J. Zaucha, J. Walewski, A. Pluta, 2022, British journal of haematology.

Clinicopathological correlates of plasma cell CD56 (NCAM) expression in multiple myeloma

Barbara Kruk, J. Woźniak, M. Kraj, 2008, Leukemia & lymphoma.

Development of extramedullary myeloma manifestations following thalidomide therapy

K. Warzocha, E. Mendek-Czajkowska, M. Kraj, 2010 .

Efficacy and safety of thalidomide in the treatment of multiple myeloma.

K. Warzocha, E. Mendek-Czajkowska, M. Kraj, 2008, Acta poloniae pharmaceutica.

Clinicopathological correlates of plasma cell CD56 (NCAM) expression in multiple myeloma

Barbara Kruk, J. Woźniak, M. Kraj, 2008, Leukemia & lymphoma.